263 related articles for article (PubMed ID: 24251796)
1. Th1 immune responses can be modulated by varying dimethyldioctadecylammonium and distearoyl-sn-glycero-3-phosphocholine content in liposomal adjuvants.
Hussain MJ; Wilkinson A; Bramwell VW; Christensen D; Perrie Y
J Pharm Pharmacol; 2014 Mar; 66(3):358-66. PubMed ID: 24251796
[TBL] [Abstract][Full Text] [Related]
2. Correlating liposomal adjuvant characteristics to in-vivo cell-mediated immunity using a novel Mycobacterium tuberculosis fusion protein: a multivariate analysis study.
Kastner E; Hussain MJ; Bramwell VW; Christensen D; Perrie Y
J Pharm Pharmacol; 2015 Mar; 67(3):450-63. PubMed ID: 25677402
[TBL] [Abstract][Full Text] [Related]
3. Lipid conjugation of TLR7 agonist Resiquimod ensures co-delivery with the liposomal Cationic Adjuvant Formulation 01 (CAF01) but does not enhance immunopotentiation compared to non-conjugated Resiquimod+CAF01.
Wilkinson A; Lattmann E; Roces CB; Pedersen GK; Christensen D; Perrie Y
J Control Release; 2018 Dec; 291():1-10. PubMed ID: 30291987
[TBL] [Abstract][Full Text] [Related]
4. Characterization of cationic liposomes based on dimethyldioctadecylammonium and synthetic cord factor from M. tuberculosis (trehalose 6,6'-dibehenate)-a novel adjuvant inducing both strong CMI and antibody responses.
Davidsen J; Rosenkrands I; Christensen D; Vangala A; Kirby D; Perrie Y; Agger EM; Andersen P
Biochim Biophys Acta; 2005 Dec; 1718(1-2):22-31. PubMed ID: 16321607
[TBL] [Abstract][Full Text] [Related]
5. Subunit vaccines: distearoylphosphatidylcholine-based liposomes entrapping antigen offer a neutral alternative to dimethyldioctadecylammonium-based cationic liposomes as an adjuvant delivery system.
McNeil SE; Rosenkrands I; Agger EM; Andersen P; Perrie Y
J Pharm Sci; 2011 May; 100(5):1856-65. PubMed ID: 21374619
[TBL] [Abstract][Full Text] [Related]
6. Cationic DDA/TDB liposome as a mucosal vaccine adjuvant for uptake by dendritic cells in vitro induces potent humoural immunity.
Qu W; Li N; Yu R; Zuo W; Fu T; Fei W; Hou Y; Liu Y; Yang J
Artif Cells Nanomed Biotechnol; 2018; 46(sup1):852-860. PubMed ID: 29447484
[TBL] [Abstract][Full Text] [Related]
7. Influence of trehalose 6,6'-diester (TDX) chain length on the physicochemical and immunopotentiating properties of DDA/TDX liposomes.
Kallerup RS; Madsen CM; Schiøth ML; Franzyk H; Rose F; Christensen D; Korsholm KS; Foged C
Eur J Pharm Biopharm; 2015 Feb; 90():80-9. PubMed ID: 25445301
[TBL] [Abstract][Full Text] [Related]
8. The vesicle size of DDA:TDB liposomal adjuvants plays a role in the cell-mediated immune response but has no significant effect on antibody production.
Henriksen-Lacey M; Devitt A; Perrie Y
J Control Release; 2011 Sep; 154(2):131-7. PubMed ID: 21640145
[TBL] [Abstract][Full Text] [Related]
9. Pegylation of DDA:TDB liposomal adjuvants reduces the vaccine depot effect and alters the Th1/Th2 immune responses.
Kaur R; Bramwell VW; Kirby DJ; Perrie Y
J Control Release; 2012 Feb; 158(1):72-7. PubMed ID: 22032883
[TBL] [Abstract][Full Text] [Related]
10. The surface charge of liposomal adjuvants is decisive for their interactions with the Calu-3 and A549 airway epithelial cell culture models.
Ingvarsson PT; Rasmussen IS; Viaene M; Irlik PJ; Nielsen HM; Foged C
Eur J Pharm Biopharm; 2014 Aug; 87(3):480-8. PubMed ID: 24726978
[TBL] [Abstract][Full Text] [Related]
11. A comparative study of cationic liposome and niosome-based adjuvant systems for protein subunit vaccines: characterisation, environmental scanning electron microscopy and immunisation studies in mice.
Vangala A; Kirby D; Rosenkrands I; Agger EM; Andersen P; Perrie Y
J Pharm Pharmacol; 2006 Jun; 58(6):787-99. PubMed ID: 16734980
[TBL] [Abstract][Full Text] [Related]
12. Incorporation of a synthetic mycobacterial monomycoloyl glycerol analogue stabilizes dimethyldioctadecylammonium liposomes and potentiates their adjuvant effect in vivo.
Nordly P; Korsholm KS; Pedersen EA; Khilji TS; Franzyk H; Jorgensen L; Nielsen HM; Agger EM; Foged C
Eur J Pharm Biopharm; 2011 Jan; 77(1):89-98. PubMed ID: 20940050
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the depot effect and immunogenicity of liposomes based on dimethyldioctadecylammonium (DDA), 3β-[N-(N',N'-Dimethylaminoethane)carbomyl] cholesterol (DC-Chol), and 1,2-Dioleoyl-3-trimethylammonium propane (DOTAP): prolonged liposome retention mediates stronger Th1 responses.
Henriksen-Lacey M; Christensen D; Bramwell VW; Lindenstrøm T; Agger EM; Andersen P; Perrie Y
Mol Pharm; 2011 Feb; 8(1):153-61. PubMed ID: 21117621
[TBL] [Abstract][Full Text] [Related]
14. Adsorption of protein antigen to the cationic liposome adjuvant CAF®01 is required for induction of Th1 and Th17 responses but not for antibody induction.
Wørzner K; Hvannastein J; Schmidt ST; Foged C; Rosenkrands I; Pedersen GK; Christensen D
Eur J Pharm Biopharm; 2021 Aug; 165():293-305. PubMed ID: 34044110
[TBL] [Abstract][Full Text] [Related]
15. Combinational PRR Agonists in Liposomal Adjuvant Enhances Immunogenicity and Protective Efficacy in a Tuberculosis Subunit Vaccine.
Hao L; Wu Y; Zhang Y; Zhou Z; Lei Q; Ullah N; Banga Ndzouboukou JL; Lin X; Fan X
Front Immunol; 2020; 11():575504. PubMed ID: 33117374
[TBL] [Abstract][Full Text] [Related]
16. Elucidating the mechanisms of protein antigen adsorption to the CAF/NAF liposomal vaccine adjuvant systems: effect of charge, fluidity and antigen-to-lipid ratio.
Hamborg M; Rose F; Jorgensen L; Bjorklund K; Pedersen HB; Christensen D; Foged C
Biochim Biophys Acta; 2014 Aug; 1838(8):2001-10. PubMed ID: 24769435
[TBL] [Abstract][Full Text] [Related]
17. A case-study investigating the physicochemical characteristics that dictate the function of a liposomal adjuvant.
Perrie Y; Kastner E; Kaur R; Wilkinson A; Ingham AJ
Hum Vaccin Immunother; 2013 Jun; 9(6):1374-81. PubMed ID: 23584249
[TBL] [Abstract][Full Text] [Related]
18. Designing CAF-adjuvanted dry powder vaccines: spray drying preserves the adjuvant activity of CAF01.
Ingvarsson PT; Schmidt ST; Christensen D; Larsen NB; Hinrichs WL; Andersen P; Rantanen J; Nielsen HM; Yang M; Foged C
J Control Release; 2013 May; 167(3):256-64. PubMed ID: 23415813
[TBL] [Abstract][Full Text] [Related]
19. Effect of incorporating cholesterol into DDA:TDB liposomal adjuvants on bilayer properties, biodistribution, and immune responses.
Kaur R; Henriksen-Lacey M; Wilkhu J; Devitt A; Christensen D; Perrie Y
Mol Pharm; 2014 Jan; 11(1):197-207. PubMed ID: 24171445
[TBL] [Abstract][Full Text] [Related]
20. Manipulation of the surface pegylation in combination with reduced vesicle size of cationic liposomal adjuvants modifies their clearance kinetics from the injection site, and the rate and type of T cell response.
Kaur R; Bramwell VW; Kirby DJ; Perrie Y
J Control Release; 2012 Dec; 164(3):331-7. PubMed ID: 22800572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
